I'm LongbridgeAI, I can summarize articles.Guggenheim maintains a Buy rating on Elevance Health with a $460 price target, implying an 11.5% upside from the Oct 9 close. The firm cites strong management outlooks in Medicaid, Medicare Advantage, and ACA segments, alongside diversified earnings and margin improvements. These factors support a de-risked setup for 2026 and targeted adjusted EPS growth exceeding 12% by 2027.
Guggenheim maintained their Buy rating on Elevance Health's stock with a price target of $460.00.
The price target implies an upside of 11.5% from the Oct 9 close of $412.70.
Key takeaways from the analyst note
Strong Management Outlook: Elevance Health has shown resilience and improvement in its key segments, particularly Medicaid, Medicare Advantage, and ACA, with management suggesting these areas are developing better than initially expected. This positive outlook is expected to bolster earnings growth and create a largely de-risked setup for 2026.
Diversified Earnings and Margin Improvement: The company's diversified earnings base and ongoing cost management initiatives provide a solid foundation for an earnings recovery. This positions Elevance Health favorably for achieving targeted adjusted EPS growth of over 12% by 2027, further justifying Guggenheim's confidence and Buy rating.
Explore more price target data and ratings for Elevance Health on the .